The startup develops a nano diagnostics technology that utilizes artificial intelligence to enhance the precision of liquid biopsies for early cancer detection through prenatal tests. This technology enables timely surgical interventions by accurately identifying cancer at its initial stages, improving patient outcomes.

Contraline is developing ADAM™, a long-lasting, non-hormonal implant for male contraception that functions similarly to an IUD. This device addresses the need for a reliable and reversible contraceptive option for men, eliminating the anxiety and inconvenience associated with current methods.

Huma provides a business intelligence platform that utilizes generative AI to automate the extraction of insights from diverse healthcare data sources. This technology enables users to conduct complex research queries and generate traceable evidence, enhancing decision-making efficiency in the life sciences sector.

Immune-Onc Therapeutics develops therapeutic antibodies that target myeloid cell surface proteins to enhance the efficacy of immunotherapy for blood cancers and solid tumors. By modulating or depleting specific myeloid cell subsets, the company aims to improve treatment outcomes for the majority of cancer patients who currently do not respond to existing therapies.

Laplace Interventional is developing a Transcatheter tricuspid valve replacement (TTVR) system for patients with Tricuspid Regurgitation. This investigational device is designed to deliver a prosthetic valve percutaneously, avoiding open-heart surgery. The goal is to potentially improve the quality of life and increase life expectancy for affected patients.

Lev is a commercial mortgage marketplace that utilizes real-time lender data and an AI-powered matching algorithm to streamline the financing process for capital market advisors. The platform enables sponsors and brokers to efficiently identify suitable lenders, manage deals, and automate follow-ups, significantly reducing the time and effort required to secure financing.

Mediar is developing therapeutics that target fibrotic mediators to neutralize myofibroblasts, the key cells responsible for collagen deposition and organ scarring in fibrosis. This approach aims to slow disease progression and promote tissue regeneration in patients suffering from fibrotic diseases.

This company provides data-driven technology solutions to empower healthcare delivery across Africa. Their platform enables patients to engage with doctors and manage health records securely within a single application. Health facilities utilize the system for efficient patient management and data-driven revenue growth, while global organizations gain access to real-time health data.

Modular provides a unified AI software development platform that enables developers to optimize and deploy AI models across various cloud environments without rewriting code. By leveraging high-performance Mojo programming and a secure inference stack, the platform significantly reduces cloud costs while enhancing computational efficiency for enterprise applications.

Neptune provides a platform that guides couples through prenuptial agreement preparation using AI-driven alignment tools. The service connects users with vetted family law attorneys offering flat-fee pricing for drafting and finalizing enforceable prenups. This process aims to facilitate financial transparency and partnership alignment before marriage.

neuro42 develops portable magnetic resonance imaging (MRI) machines that integrate artificial intelligence and robotics for real-time imaging and guidance during neurological procedures. This technology enables rapid diagnosis and targeted interventions for conditions such as stroke, tumors, and epilepsy, improving patient outcomes by facilitating immediate imaging in critical care settings.

ON is an AI chat platform designed for enterprise use, integrating with e-commerce systems like Shopify to enhance customer interactions by providing real-time access to product and order information. This technology addresses the high volume of customer service inquiries, improving site conversions and customer satisfaction while reducing the workload for support agents.

Presidio Medical is developing a neuromodulation platform utilizing Ultra Low Frequency (ULF™) current waveforms to inhibit pain signals by inactivating sodium channels in neurons. This technology aims to provide a reversible treatment for chronic pain, addressing the limitations of existing therapies and reducing reliance on opioids.

Pykus Therapeutics is developing PYK-2101, a biodegradable retinal sealant that eliminates the need for facedown positioning and reduces blurred vision during recovery from retinal surgery. This technology addresses the significant post-operative burdens faced by patients, enhancing their overall recovery experience.

Quan provides a science-backed employee well-being platform that utilizes evidence-based assessments to measure dimensions of well-being, enabling teams to identify strengths and risks. By facilitating structured quarterly discussions and recommending targeted rituals, Quan helps organizations enhance team performance and prevent burnout.

The startup is developing a multi-chain wallet specifically designed for the media and entertainment sector, enabling users to securely manage digital assets across various blockchain networks. This solution addresses the challenge of fragmented asset management by providing a unified platform for seamless transactions and storage of digital media assets.

Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.

Setpoint offers a cloud‑based operating system that automates data ingestion, calculations, reporting, and compliance for warehouse facilities, forward flow, securitization, and other asset‑backed financing workflows. By connecting borrowers and lenders through configurable, API‑driven workflows and AI‑powered analytics, the platform enables intraday funding, real‑time loan‑level monitoring, and instant investor reporting, cutting funding times to under 24 hours and reducing operational costs for institutional banks and originators.

Skyhawk Therapeutics develops small molecule therapeutics that modify RNA expression to target diseases such as Huntington's Disease, with its lead candidate, SKY-0515, demonstrating a 72% reduction in HTT mRNA during clinical trials. The company's proprietary SKYSTAR® platform accelerates the creation of RNA-targeting drugs across neurology, oncology, and fibrotic diseases, addressing significant unmet medical needs.

The startup has developed a medical device that utilizes alternating magnetic fields generated by external coils to eliminate biofilm from the surfaces of infected metallic implants. This non-invasive treatment addresses complications associated with surgeries such as knee and hip replacements, as well as trauma-related implants like plates and rods.

This company develops contact lens care products and disposable lenses featuring a polymer-based coating technology. This technology creates a biocompatible, hydrated lens surface that prevents tear film disruption, aiming to eliminate dry eye symptoms for contact lens wearers.

tem. provides businesses with a platform to purchase 100% renewable energy directly from generators, reducing energy costs by an average of 25% while ensuring full traceability of energy sources. By eliminating intermediary fees, tem. facilitates a more transparent and cost-effective energy transition for companies committed to sustainability.

TrueBinding is developing TB006, a humanized monoclonal antibody that selectively inhibits Galectin‑3 to reduce chronic inflammaging, with engineered Fc modifications that enable brain penetration and microglial modulation. The company provides an FDA‑authorized Expanded Access Program for patients with dementia or Alzheimer’s who lack other treatment options, while advancing Phase 1b/2a and Phase 2a trials in Alzheimer’s and Parkinson’s disease.

Window Therapeutics develops targeted cancer therapeutics using proprietary Bottle-brush-Analogue-Macromonomer (BAM) technology to enhance drug efficacy while significantly reducing systemic toxicity. This platform augments the activity of various drug classes, enabling deeper penetration into diseased tissue for localized treatment. The technology aims to widen the therapeutic window, offering clinicians more effective and safer treatment regimens for cancer patients.